George Coukos

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
    Lana E Kandalaft
    Ovarian Cancer Research Center University of Pennsylvania School of Medicine Philadelphia, PA USA
    Oncoimmunology 2:e22664. 2013
  2. pmc A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
    Lana E Kandalaft
    Ovarian Cancer Research Center, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA
    J Transl Med 10:157. 2012
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  4. pmc The role of dendritic cell precursors in tumour vasculogenesis
    G Coukos
    Abramson Family Cancer Research Institute, University of Pennsylvania, BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Br J Cancer 92:1182-7. 2005
  5. doi Immunotherapy opportunities in ovarian cancer
    Christina S Chu
    University of Pennsylvania, Division of Gynecologic Oncology, Center for Research on Ovarian Cancer, PA, USA
    Expert Rev Anticancer Ther 8:243-57. 2008
  6. ncbi Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm
    George Coukos
    Center for Research on Reproduction and Women s Health, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia 19104, USA
    Curr Gene Ther 3:113-25. 2003
  7. ncbi Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer
    Lin Zhang
    Abramson Family Cancer Research Institute, Philadelphia, PA 19104, USA
    Biochem Biophys Res Commun 303:1169-78. 2003
  8. ncbi Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:264-72. 2003
  9. pmc Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Am J Pathol 161:2295-309. 2002
  10. pmc Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer
    Heather L Pulaski
    Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA
    J Transl Med 7:49. 2009

Collaborators

Detail Information

Publications111 found, 100 shown here

  1. pmc Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
    Lana E Kandalaft
    Ovarian Cancer Research Center University of Pennsylvania School of Medicine Philadelphia, PA USA
    Oncoimmunology 2:e22664. 2013
    ..Several modifications of this approach can be envisioned to optimize immunological and clinical outcomes...
  2. pmc A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer
    Lana E Kandalaft
    Ovarian Cancer Research Center, Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, USA
    J Transl Med 10:157. 2012
    ..In spite of increased rates of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease...
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  4. pmc The role of dendritic cell precursors in tumour vasculogenesis
    G Coukos
    Abramson Family Cancer Research Institute, University of Pennsylvania, BRBII III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Br J Cancer 92:1182-7. 2005
    ..The identification of dendritic cell precursors as bipotent cells has important implications for the physiopathology and therapy of tumours. VLCs emerge as a novel therapeutic target against tumour vascularisation...
  5. doi Immunotherapy opportunities in ovarian cancer
    Christina S Chu
    University of Pennsylvania, Division of Gynecologic Oncology, Center for Research on Ovarian Cancer, PA, USA
    Expert Rev Anticancer Ther 8:243-57. 2008
    ..Additional combinatorial approaches include the use of cytokines and/or chemotherapy with immune therapy...
  6. ncbi Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: the herpes paradigm
    George Coukos
    Center for Research on Reproduction and Women s Health, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, and Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia 19104, USA
    Curr Gene Ther 3:113-25. 2003
    ..We review the preclinical evidence on the efficacy and safety of intraperitoneal applications of HSV and discuss the rationale for its use for oncolytic therapy and in situ tumor vaccination of intraperitoneal tumors...
  7. ncbi Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer
    Lin Zhang
    Abramson Family Cancer Research Institute, Philadelphia, PA 19104, USA
    Biochem Biophys Res Commun 303:1169-78. 2003
    ..This strategy provides a novel tool to study the function of various VEGF isoforms and may contribute to VEGF isoform-specific treatment in cancer...
  8. ncbi Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:264-72. 2003
    ..We postulate that EG-VEGF-targeted antiangiogenic therapy may prove useful in early stage but not in advanced stage ovarian carcinoma...
  9. pmc Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Am J Pathol 161:2295-309. 2002
    ....
  10. pmc Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer
    Heather L Pulaski
    Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, USA
    J Transl Med 7:49. 2009
    ..Abundant VLC and Tie2+ monocytes have been reported in human cancer. Unfortunately, the importance of VLC in human cancer growth remains untested as there are no confirmed therapeutics to target human VLC...
  11. pmc KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer
    Kiranmai Gumireddy
    The Wistar Institute, 3601 Spruce Street, PA 19104, USA
    Nat Cell Biol 11:1297-304. 2009
    ....
  12. pmc Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells
    Xiaojun Yang
    Center for Research on Early Detection and Cure of Ovarian Cancer, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 70:9463-72. 2010
    ..Our data provide evidence that cancer stem cells may arise through a "reprogramming-like" mechanism. A rebalancing of the LIN28/let-7 regulatory loop could be a novel therapeutic strategy to target ALDH1+ cancer stem cells...
  13. pmc Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
    Ioannis Alagkiozidis
    Ovarian Cancer Research Center, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Transl Med 9:77. 2011
    ..Here, we investigated the potential use of anticancer chemotherapeutic drugs in combination with IL-18, a cytokine with strong immunostimulatory properties...
  14. pmc Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment
    Nuo Yang
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 3:e1758. 2008
    ..These results offer a new mechanism through which the tumor microenvironment directly activates oncogenic pathways in tumor cells...
  15. ncbi The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma
    Lin Zhang
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:4225-31. 2003
    ....
  16. pmc Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses
    Cheryl Lai Lai Chiang
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 6:e28732. 2011
    ....
  17. ncbi HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer
    Fabian Benencia
    Abramson Family Cancer Research Institute, Philadelphia, PA 19104, USA
    Mol Ther 12:789-802. 2005
    ..These results indicate that HSV-1716 induces an inflammatory response that may facilitate antitumor immune response upon oncolytic therapy...
  18. pmc Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma
    Andrea R Hagemann
    Ovarian Cancer Research Center, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, USA
    Cancer Biol Ther 12:367-77. 2011
    ..In conclusion, between-site heterogeneity exists in some patients with metastatic serous ovarian cancer. The predictive value of biopsies should be considered in clinical trial design...
  19. pmc A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
    Lana E Kandalaft
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA
    J Transl Med 11:149. 2013
    ....
  20. pmc miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer
    Antonis Giannakakis
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 7:255-64. 2008
    ..Taken together, our results indicate that miR-210 plays a crucial role in tumor onset as a key regulator of the hypoxia response and provide evidence for a link between hypoxia and the regulation of cell cycle...
  21. ncbi Tumor vascular proteins as biomarkers in ovarian cancer
    Ronald J Buckanovich
    Center for Research on Reproduction and Women s Health, Abramson Family Cancer Research Institute, Department of Medicine Division of Hematology Oncology, Philadelphia, PA, USA
    J Clin Oncol 25:852-61. 2007
    ..This study aimed to identify novel ovarian cancer biomarkers and potential therapeutic targets through molecular analysis of tumor vascular cells...
  22. pmc MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer
    Nuo Yang
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 68:10307-14. 2008
    ..049). Taken together, our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer...
  23. ncbi Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 66:4627-35. 2006
    ..We propose that PKCiota may serve as an oncogene and a biomarker of aggressive disease in human ovarian cancer...
  24. pmc Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization
    Selene Nunez-Cruz
    Penn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neoplasia 14:994-1004. 2012
    ..Finally, the mouse VEGF(164) transcript was underexpressed in C3(KO) livers compare to C3(WT) livers. Thus, we conclude that complement inhibition blocks tumor outgrowth by altering EC function and VEGF(165) expression...
  25. doi Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
    Christina S Chu
    Department of Obstetrics and Gynecology and Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Immunol Immunother 61:629-41. 2012
    ..In spite of increased rates of complete response to initial chemotherapy, most patients with advanced ovarian cancer relapse and succumb to progressive disease. Immunotherapy may have potential for consolidation therapy...
  26. ncbi Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
    Ronald J Buckanovich
    Center for Research on Ovarian Cancer Early Detection and Cure, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Med 14:28-36. 2008
    ..These findings highlight a molecular mechanism with the potential to be pharmacologically manipulated to enhance the efficacy of tumor immunotherapy in humans...
  27. ncbi Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth
    Lin Zhang
    Abramson Family Cancer Research Institute, Center for Research on Reproduction and Women s Health, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Cancer Res 65:925-32. 2005
    ..Therefore, this study suggests an important role of EYA2 in ovarian cancer and its potential application as a therapeutic target...
  28. ncbi Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma
    Fabian Benencia
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
    Hum Gene Ther 16:765-78. 2005
    ..We conclude that oncolytic HSV-1716 exerts direct antiangiogenic effects, which may contribute to the overall therapeutic efficacy of the virus...
  29. ncbi Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity
    Fabian Benencia
    Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 5:867-74. 2006
    ..Thus, the use of replication-incompetent HSV strains lacking ICP4 offers possible advantages in the preparation of whole tumor cell antigen for direct tumor vaccination...
  30. pmc CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor
    Qunrui Ye
    Authors Affiliations Department of Obstetrics and Gynecology, Ovarian Cancer Research Center and Department of Pathology and Laboratory Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
    Clin Cancer Res 20:44-55. 2014
    ....
  31. pmc A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside
    Cheryl Lai Lai Chiang
    Ovarian Cancer Research Center, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 19:4801-15. 2013
    ..Hypochlorous acid (HOCl) oxidation is a new method for inducing primary necrosis and enhancing the immunogenicity of tumor cells...
  32. ncbi Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A
    Jose R Conejo-Garcia
    Center for Research in Reproduction and Women s Health, University of Pennsylvania Medical Center, BRBII III, 421 Curie Blvd, Philadelphia, Pennsylvania 19104, USA
    Nat Med 10:950-8. 2004
    ....
  33. pmc Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer
    Sarah F Adams
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Cancer 115:2891-902. 2009
    ....
  34. pmc Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
    Lin Zhang
    Center for Research on Early Detection and Cure of Ovarian Cancer and Gynecology, Department of Obstetrics, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 105:7004-9. 2008
    ..Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer...
  35. ncbi RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer
    Lin Zhang
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 3:1283-9. 2004
    ..This strategy provides a novel tool to study the function of various PI3-kinase isoforms and may contribute to isoform-specific targeting of PI3-kinase in human cancer...
  36. ncbi Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer
    Lin Zhang
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 13:5314-21. 2007
    ..Here, we investigated the genomic alterations and gene expression of most known PI3K family members in human epithelial ovarian cancer...
  37. pmc Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18
    Ioannis Alagkiozidis
    Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    J Transl Med 7:104. 2009
    ..Its active drug, doxorubicin, has interesting immunomodulatory properties. Here, the effects of Doxil on surviving tumor cell immunophenotype were investigated...
  38. pmc Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers
    Shan Deng
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 5:e10277. 2010
    ..As a novel cancer stem cell marker, ALDH1 can be used for tumors whose corresponding normal tissues express ALDH1 in relatively restricted or limited levels such as breast, lung, ovarian or colon cancer...
  39. pmc Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment
    Andrea R Hagemann
    Ovarian Cancer Research Center, Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia, USA
    Cancer Biol Ther 12:357-66. 2011
    ..Our results demonstrate a feasible and reproducible method of immune monitoring using CT-compatible needle biopsies from tumor tissue, thereby paving the way for sophisticated translational studies during tumor biological therapy...
  40. pmc Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer
    David O Holtz
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, USA
    J Transl Med 6:2. 2008
    ..This is the first preclinical study that models interactions of LD paclitaxel chemotherapy with antiangiogenic therapy and tumor VEGF expression and offers important lessons for the rational design of clinical trials...
  41. ncbi Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer
    Lin Zhang
    Abramson Family Cancer Research Institute, Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 63:3403-12. 2003
    ....
  42. pmc Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate
    Cheryl L L Chiang
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, 19104, USA
    J Transl Med 9:198. 2011
    ..Due to the wide range of methods for generating DCs, there is no common protocol or defined set of criteria to validate the immunogenicity and function of DC vaccines...
  43. pmc Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor
    Evripidis Lanitis
    Department of Obstetrics and Gynecology, Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Mol Ther 20:633-43. 2012
    ....
  44. pmc Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells
    Fabian Benencia
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, PA, USA
    J Transl Med 6:21. 2008
    ....
  45. pmc Novel surface targets and serum biomarkers from the ovarian cancer vasculature
    Dimitra Sasaroli
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA USA
    Cancer Biol Ther 12:169-80. 2011
    ..We have identified novel tumor-specific vasculature markers which appear promising for cancer serum diagnostics, molecular imaging and/or therapeutic targeting applications and warrant further clinical development...
  46. pmc Involvement of endothelial CD44 during in vivo angiogenesis
    Gaoyuan Cao
    Pulmonary, Allergy and Critical Care Division, Department of Medicine, Division of Neonatology, Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Am J Pathol 169:325-36. 2006
    ..These data establish a role for CD44 during in vivo angiogenesis and suggest that CD44 may contribute to the organization and/or stability of developing endothelial tubular networks...
  47. ncbi TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients
    Katia Schlienger
    Abramson Family Cancer Research Institute, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 9:1517-27. 2003
    ..We also sought to measure preexisting antitumor immunity in patients with advanced ovarian cancer...
  48. ncbi Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment
    Ronald J Buckanovich
    Center for Research on Reproduction and Women s Health, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 5:635-42. 2006
    ..We propose that immuno-LCM coupled with transcriptional profiling is a convenient tool for dissecting molecular and cellular events in complex biological systems such as the tumor microenvironment...
  49. pmc microRNAs exhibit high frequency genomic alterations in human cancer
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 103:9136-41. 2006
    ..These findings support the notion that copy number alterations of miRNAs and their regulatory genes are highly prevalent in cancer and may account partly for the frequent miRNA gene deregulation reported in several tumor types...
  50. pmc Whole tumor antigen vaccines
    Cheryl Lai Lai Chiang
    Ovarian Cancer Research Center, University of Pennsylvania Medical Center, USA
    Semin Immunol 22:132-43. 2010
    ....
  51. pmc Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels
    Evripidis Lanitis
    Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 7:e49829. 2012
    ....
  52. pmc Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation
    Shun Liang
    Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America
    PLoS ONE 4:e4295. 2009
    ..Our in vivo data suggests that PIK3CA activation is one of the early genetic events in ovarian cancer. However, its role in malignant transformation of ovarian surface epithelium (OSE) is largely unclear...
  53. pmc A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer
    Ning Li
    Ovarian Cancer Research Center and Department of Obstetrics and Gynecology, University of Pennsylvania, Wistar Institute, Philadelphia, Pennsylvania, USA
    Cancer Res 72:154-64. 2012
    ..The guided genetic screening approach validated by this study offers a powerful tool to identify oncomirs that may have utility as biomarkers or targets for drug development...
  54. pmc Therapeutic microRNA strategies in human cancer
    Chunsheng Li
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    AAPS J 11:747-57. 2009
    ..Therefore, it has been proposed that manipulating miRNA activity and miRNA biogenesis may be a novel avenue for developing efficient therapies against cancer...
  55. doi Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells
    Andrea Facciabene
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nature 475:226-30. 2011
    ..Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth...
  56. doi The parallel lives of angiogenesis and immunosuppression: cancer and other tales
    Gregory T Motz
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Immunol 11:702-11. 2011
    ..This view can help to devise new cancer therapies and may have implications for aseptic tissue injury, pathogen-mediated tissue destruction, chronic inflammation and even reproduction...
  57. ncbi Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion
    Brian J Czerniecki
    Department of Surgery, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Cancer Res 67:1842-52. 2007
    ..DC1 vaccination strategies may therefore have potential for both the prevention and the treatment of early breast cancer...
  58. ncbi Vascular leukocytes contribute to tumor vascularization
    Jose R Conejo-Garcia
    Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, USA
    Blood 105:679-81. 2005
    ..Our data provide an important link between hematopoietic endothelial precursors and vascular development in postnatal life and a possible novel therapeutic target...
  59. ncbi miRNA genetic alterations in human cancers
    Antonis Giannakakis
    University of Pennsylvania School of Medicine, Center for Research on Early Detection and Cure of Ovarian Cancer, Rm1209 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Expert Opin Biol Ther 7:1375-86. 2007
    ..The aim of this review is to describe miRNA expression and how its deregulation is involved in the pathophysiology of human cancers...
  60. pmc Immunotherapy for ovarian cancer: what's next?
    Lana E Kandalaft
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA
    J Clin Oncol 29:925-33. 2011
    ..Herein, we review current progress and future prospects in vaccine and adoptive T-cell therapy development as well as immunomodulatory therapy tools available for immediate clinical testing...
  61. ncbi Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation
    Fabian Benencia
    Center for Research on Ovarian Cancer Early Detection and Cure, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Biol Ther 7:1194-205. 2008
    ..These results indicate that oncolytic therapy with HSV-1716 facilitates antitumor immune responses...
  62. ncbi Mechanisms of microRNA deregulation in human cancer
    Shan Deng
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cell Cycle 7:2643-6. 2008
    ..A clearer understanding of the mechanisms involved in miRNA deregulation in human cancer will contribute greatly to the development of new miRNA-based strategies in cancer diagnosis and treatment...
  63. pmc Endothelin B receptor, a new target in cancer immune therapy
    Lana E Kandalaft
    Ovarian Cancer Research Center University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 15:4521-8. 2009
    ..We also review our recent findings on the effects of ET(B)R-specific blockade in increasing T-cell homing to tumors and enhancing the efficacy of otherwise ineffective immunotherapy...
  64. ncbi Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells
    Jose R Conejo-Garcia
    Center for Research in Reproduction and Women s Health, University of Pennsylvania Medical Center, 421 Curie Boulevard, Philadelphia, PA 19104, USA
    Cancer Res 64:2175-82. 2004
    ..We propose that Letal could be used for the ex vivo expansion of apoptosis-resistant tumor-reactive cytotoxic lymphocytes for adoptive transfer...
  65. pmc Immune prognostic factors in ovarian cancer: lessons from translational research
    Phyllis A Gimotty
    Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Dis Markers 23:445-52. 2007
  66. pmc Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome
    Jia Huang
    Department of Biology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Genes Chromosomes Cancer 50:606-18. 2011
    ..Both mutation as well as copy number changes can be used as predictive markers for this purpose...
  67. doi The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis
    Qihong Huang
    The Wistar Institute, 3601 Spruce Street, Philadelphia, PA 19104, USA
    Nat Cell Biol 10:202-10. 2008
    ..Taken together, our findings indicate that miRNAs are involved in tumour migration and invasion, and implicate miR-373 and miR-520c as metastasis-promoting miRNAs...
  68. pmc In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB)
    De Gang Song
    Ovarian Cancer Research Center, Department of Obstetrics and Gynecology and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 71:4617-27. 2011
    ....
  69. ncbi Immunotherapy for gynaecological malignancies
    George Coukos
    Abramson Cancer Research Institute, Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
    Expert Opin Biol Ther 5:1193-210. 2005
    ..This review outlines the principles and problems of immunotherapy for cervical and ovarian cancer, including the authors' personal assessment...
  70. ncbi Interferon beta adenoviral gene therapy in a patient with ovarian cancer
    Daniel H Sterman
    Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, PA, USA
    Nat Clin Pract Oncol 3:633-9. 2006
    ..Diagnosis Stage IV ovarian cancer with malignant ascites and pleural effusion. Management Tunneled pleural catheter and intrapleural adenoviral-mediated interferon beta gene therapy...
  71. pmc Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer
    Jaikumar Duraiswamy
    Authors Affiliations Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts and Department of Oncology and Ludwig Center for Cancer Research, University Hospital of Lausanne, Lausanne, Switzerland
    Cancer Res 73:6900-12. 2013
    ..Overall, PD-1/PD-L1 blockade enhanced the amplitude of tumor immunity by reprogramming suppressive and stimulatory signals that yielded more powerful cancer control...
  72. pmc Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes
    Qunrui Ye
    Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    J Transl Med 9:131. 2011
    ..Development of a standardized platform for the rapid expansion of tumor-infiltrating lymphocytes (TILs) with anti-tumor function from patients with limited TIL numbers or tumor tissues challenges their clinical application...
  73. doi Tumor vascular biomarkers: new opportunities for cancer diagnostics
    Chunsheng Li
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA, USA
    Cancer Biomark 8:253-71. 2010
    ..The aim of the current review is to provide a synopsis of recent advancements in the identification of tumor vasculature biomarkers...
  74. pmc miRNAs in human cancer
    Xiaomin Zhong
    Department of Obstetrics and Gynecology, Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, PA, USA
    Methods Mol Biol 822:295-306. 2012
    ..Large-scale studies in human cancer have further demonstrated that miRNA expression signatures are associated not only with specific tumor subtypes but also with clinical outcomes...
  75. pmc Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells
    Richard G Carroll
    Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    PLoS ONE 3:e3289. 2008
    ..These preclinical data suggest that human IL-18 may have use as an adjuvant for immune reconstitution after cytotoxic therapies, and to augment adoptive immunotherapy, donor leukocyte infusions, and vaccine strategies...
  76. pmc The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade
    Lana E Kandalaft
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Gynecol Oncol 116:222-33. 2010
    ..We will also review how existing drugs can be used for combinatorial tumor therapy...
  77. ncbi Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
    Lin Zhang
    Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia 19104, USA
    N Engl J Med 348:203-13. 2003
    ..Although tumor-infiltrating T cells have been documented in ovarian carcinoma, a clear association with clinical outcome has not been established...
  78. doi Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin
    Lana E Kandalaft
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Curr Top Microbiol Immunol 344:129-48. 2011
    ..These insights establish new targets for combinatorial approaches to modify existing cancer immunotherapies...
  79. ncbi MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment
    Nuo Yang
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Int J Cancer 122:963-8. 2008
    ....
  80. doi Role of vascular leukocytes in ovarian cancer neovascularization
    Klara Balint
    Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia 19104, USA
    Adv Exp Med Biol 622:273-80. 2008
    ..Vascular leukocytes are a new and promising novel therapeutic target for anti-angiogenic therapy. Their unique mechanism merits thorough and extensive exploration in the future...
  81. ncbi The fibronectin receptor alpha5 integrin subunit is upregulated by cell-cell adhesion via a cyclic AMP-dependent mechanism: implications for human trophoblast migration
    Christos Coutifaris
    Division of Reproductive Endocrinology and Infertility, University of Pennsylvania Medical Center, Suite 800, 3701 Market St, Philadelphia, PA 19104 6142, USA
    Am J Obstet Gynecol 192:1240-53; discussion 1253-5. 2005
    ..It is hypothesized that these mechanisms may play an important role in the molecular events controlling human placentation...
  82. doi Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance
    Lana E Kandalaft
    Ovarian Cancer Research Center, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Metastasis Rev 30:141-51. 2011
    ..We believe that understanding these pathways in the tumor microenvironment will lead to novel strategies for enhancing ovarian cancer immunotherapy...
  83. ncbi MicroRNAs: a new insight into cancer genome
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Cell Cycle 5:2216-9. 2006
    ..Mounting evidence is showing that miRNAs may play important roles in tumor development, and a better understanding of their alteration in cancer genome and oncogenic property should contribute to the diagnosis and treatment of cancer...
  84. ncbi Complete hydatidiform mole. A disease with a changing profile
    G Coukos
    Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Reprod Med 44:698-704. 1999
    ..To retrospectively evaluate the clinical presentation of complete molar pregnancies in an academic primary obstetrics and gynecology practice over the past decade...
  85. ncbi Gene therapy for ovarian cancer
    G Coukos
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA
    Oncology (Williston Park) 15:1197-204, 1207; discussion 1207-8. 2001
    ..However, clinical trials will need to test these hypotheses...
  86. ncbi Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer
    G Coukos
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Clin Cancer Res 6:3342-53. 2000
    ..These data support the hypothesis that HSV-based oncolytic therapy may be efficacious in chemotherapy-resistant tumors, including tumors that are deficient in p53...
  87. ncbi Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines
    M C Courreges
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, PA 19104, USA
    Cancer Gene Ther 13:182-93. 2006
    ..Thus, the use of replication-incompetent HSV strains lacking immediate early genes except ICP0 offers possible advantages in the preparation of whole tumor cell antigen for DC-based tumor vaccination...
  88. ncbi Prophylactic oophorectomy
    George Coukos
    Division of Gynecologic Oncology, University of Pennsylvania Medical Center, 1000 Courtyard, 3400 Spruce Street, Philadelphia, PA 19104, USA
    Best Pract Res Clin Obstet Gynaecol 16:597-609. 2002
    ..Additionally, routine salpingo-oophorectomy in patients over 40 years undergoing scheduled gynaecological surgery or colorectal surgery might reduce the overall incidence of ovarian cancer by as much as 5% in the general population...
  89. ncbi Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells
    Lin Zhang
    Center for Research on Reproduction and Women s Health, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biochem Biophys Res Commun 292:860-8. 2002
    ..Our results indicate that under metabolic stress conditions VEGF144 is the most dramatically up-regulated VEGF isoform, probably through mechanism(s) different from the three abundant VEGF isoforms...
  90. doi MicroRNA in human cancer: one step forward in diagnosis and treatment
    Lin Zhang
    Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia, 19104, USA
    Adv Exp Med Biol 622:69-78. 2008
  91. pmc Modulation of the antitumor immune response by complement
    Maciej M Markiewski
    Department of Pathology and Laboratory Medicine, Medical School of the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Nat Immunol 9:1225-35. 2008
    ..Thus, our study demonstrates a therapeutic function for complement inhibition in the treatment of cancer...
  92. doi Inhibitory B7 family members in human ovarian carcinoma
    Shuang Wei
    Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia 19104, USA
    Adv Exp Med Biol 622:261-71. 2008
  93. pmc In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes
    Natalie A Christian
    Department of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, 210 S 33rd Street Room 240 Skirkanich Hall, Philadelphia, PA 19104, USA
    Mol Imaging Biol 11:167-77. 2009
    ..Fluorescence is commonly used for in vitro and postmortem biomedical studies but has been limited by autofluorescence at the whole-animal level...
  94. doi Regulatory T cells: a new frontier in cancer immunotherapy
    Brian G Barnett
    Center for Research on the Early Detection and Cure of Ovarian Cancer, University of Pennsylvania, Philadelphia 19104, USA
    Adv Exp Med Biol 622:255-60. 2008
  95. ncbi Ultraconserved elements: genomics, function and disease
    Eirini Baira
    Center for Research on Early Detection and Cure of Ovarian Cancer, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    RNA Biol 5:132-4. 2008
    ..Most recent studies show that expression of UCEs is consistently altered in tumors, strongly suggesting these elements may also be involved in human disease such as cancer development...
  96. ncbi Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation
    Stephanie V Blank
    Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
    Hum Gene Ther 13:627-39. 2002
    ..These results suggest that replication-selective HSV-1 mutants may be potent oncolytic agents for the treatment of cervical cancer...
  97. ncbi Inhibitory G protein alpha subunit (Gi alpha) expression and localization during human trophoblast differentiation
    E Daiter
    Department of Obstetrics and Gynecology and Center for Research in Women s Health and Reproduction, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    Eur J Obstet Gynecol Reprod Biol 88:165-9. 2000
    ....
  98. ncbi Regulated expression and potential roles of p53 and Wilms' tumor suppressor gene (WT1) during follicular development in the human ovary
    A Makrigiannakis
    Center for Research on Reproduction and Women s Health, Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia 19104, USA
    J Clin Endocrinol Metab 85:449-59. 2000
    ..We propose that the products of these two principal tumor suppressor genes serve as important regulators of human follicular development and corpus luteum function...
  99. ncbi Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer
    E Y Woo
    Department of Surgery, Abramson Family Cancer Research Institute, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 61:4766-72. 2001
    ..These observations provide evidence for the contribution of regulatory T cells to immune dysfunction in cancer patients...

Research Grants2

  1. Vascular Leukocytes Induce regulatory T cells (Treg) in Tumors
    George Coukos; Fiscal Year: 2010
    ....
  2. Endothelial Regulation of T Cell Homing in Ovarian Carcinoma
    George Coukos; Fiscal Year: 2007
    ..Results obtained from the proposed studies will generate novel ideas for the development of molecular tools to circumvent impediments to tumor immunotherapy. ..